Related Experiment Video

Updated: Mar 19, 2026

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

8.7K

Re: Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: A Prospective Development

Giuseppe Simone1, Umberto Anceschi1, Michele Gallucci1

  • 1"Regina Elena" National Cancer Institute, Department of Urology, Rome, Italy.

European Urology
|June 16, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.0K
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

22.6K

Related Experiment Videos

Last Updated: Mar 19, 2026

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

8.7K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.0K
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

22.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

Articles linked to this work by shared authors, journal, and citation graph.

Development and internal validation of machine-learning models to predict adverse pathological features in upper tract urothelial carcinoma.

Urologic oncology·2026

Perioperative and survival outcomes of synchronous vs. metachronous upper tract urothelial carcinoma among bladder cancer patients treated with radical cystectomy and nephroureterectomy: Results from an International Multicenter Collaborative Study-On behalf of the Young Academic Urology (YAU) Urothelial Working Group.

Urologic oncology·2026

Oncological outcomes of radical nephroureterectomy with or without lymphadenectomy and neoadjuvant therapy in cN+ UTUC: Insights from the ROBUUST registry.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026

Electronic nose-based urinary volatilome profiling accurately discriminates bladder cancer from healthy controls: A prospective diagnostic study.

Urologic oncology·2026

VI-RADS Score Performance in the Post-TURBT Setting: Exploring the Need for Modification.

European urology oncology·2026

Robotic intracorporeal modified Bordeaux versus Padua ileal bladder: head-to-head surgical technique, perioperative and functional outcomes.

Minerva urology and nephrology·2026

Challenges of Using Circulating Tumour DNA: Insights from Advanced Prostate Cancer.

European urology·2026

Impact of Treatment Intensification with Abiraterone on Fracture-related Hospitalisation in Newly Diagnosed Prostate Cancer: A Secondary Analysis of Two Randomised Phase 3 Trials Within the STAMPEDE Trial Platform.

European urology·2026

Why Look Further When the Solution Is in Front of You - or Is It? The Value of Confirmatory PSA in Prostate Cancer Screening.

European urology·2026

Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial.

European urology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us